In: Non-small cell lung cancer

Datopotamab deruxtecan

Daiichi Sankyo · AstraZeneca · DS-1062a · DS-1062

FollowEvery change as it happens, and a Monday email
Stage
in the US and EU
Next date
Phase 3 trial completes
Trials
33 active
34 in total · 28 in the EU
Targets
 

What this is

How it works
TROP2-targeted antibody-drug conjugate
How it’s given
“Commercially available Dato-DXd is prescribed and administered to participants according to standard of care”In the company’s words, NCT07357597 on ClinicalTrials.gov
Tested for
Non-small Cell Lung Cancer (10 trials), Breast Cancer (7 trials), Urothelial Cancer (3 trials), Non-small Cell Lung Cancer (NSCLC) (2 trials), Metastatic Non Small Cell Lung Cancer (2 trials), Bladder Cancer (2 trials), Endometrial Cancer (2 trials), Gastric Cancer (2 trials) and 22 more
Main trialPhase 4
“This is a multicenter, open-label, single-arm study of prophylaxis for Dato-DXd-related stomatitis in eligible patients with metastatic or inoperable locally recurrent breast cancer or locally advanced or metastatic Epidermal Growth Factor Receptor-Mutated (EGFRm) non-small cell lung cancer”In the company’s words, NCT07357597 on ClinicalTrials.gov
Other names
DS-1062a · DS-1062 · Dato-DXd · Datroway

Other drugs for Non-small Cell Lung Cancer

All 560 drugs for Non-small Cell Lung Cancer

Coming up12

Changes1

Last 90 days

Trials34

TrialPhaseCompletesWhat it tests
Phase 4Recruiting 4 Jan 2028 An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.
Phase 3Active, not recruiting 10 May 2024 Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
Phase 3Active, not recruiting 24 Jul 2024 A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
Phase 3Active, not recruiting 25 Aug 2025 A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
Phase 3Active, not recruiting 10 Jul 2026 A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
Phase 3Active, not recruiting 11 Jan 2027 A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 3Recruiting 28 Jul 2027 A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Phase 3Active, not recruiting 1 Sep 2027 A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
Phase 3Active, not recruiting 1 Nov 2027 Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
Phase 3Recruiting 2 Feb 2028 A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
Phase 3Recruiting 21 Mar 2028 Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase 3Active, not recruiting 20 Nov 2028 A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
Phase 3Recruiting 29 Jan 2029 Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Phase 3Active, not recruiting 11 May 2029 Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
Phase 3Recruiting 28 Dec 2029 Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Phase 3Active, not recruiting 4 Mar 2030 Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Phase 3Recruiting 11 Sep 2030 An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Phase 2/3Recruiting 1 Jun 2029 Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Phase 2Active, not recruiting 6 May 2025 Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
Phase 2Recruiting 1 Oct 2027 Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Phase 2Not yet recruiting 16 Dec 2028 A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLC
Phase 2Recruiting 6 Apr 2029 A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
Phase 2Recruiting 28 May 2030 Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Phase 1/2Active, not recruiting 7 Nov 2023 A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)
Phase 1/2Active, not recruiting 29 Nov 2024 A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
Phase 1/2Active, not recruiting 28 May 2027 Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
Phase 1/2Recruiting 7 Feb 2028 Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Phase 1/2Recruiting 4 Dec 2028 A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors
Phase 1/2Recruiting 30 Sep 2029 A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]
Phase 1Active, not recruiting 14 Apr 2024 Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)
Phase 1Active, not recruiting 4 May 2026 Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 1Active, not recruiting 1 Jan 2028 First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
Phase 1Active, not recruiting 1 Nov 2028 A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
Phase 2Completed 10 Mar 2023 Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Datopotamab deruxtecan

Following is part of Solo: you see every change to Datopotamab deruxtecan the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in